Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by ...

If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last ...

Influencer Jake Kind — known on TikTok as Goobi Gubbi — has finally opened the lockbox his late grandmother Mimmy left for his family in Switzerland after a two-week trip Mimmy, who was beloved on ...

The tussle between Team India and the ACC Chairman and PCB Chief Mohsin Naqvi doesn't seem to be ending soon over the Asia Cup trophy. It has been almost two weeks since India defeated Pakistan in the ...

According to a series of tests by NBC News, ChatGPT can be manipulated into providing information on how to construct biological, nuclear bombs and other weapons of mass destruction. Minerva Studio - ...

OpenAI’s ChatGPT has guardrails that are supposed to stop users from generating information that could be used for catastrophic purposes, like making a biological or nuclear weapon. But those ...

We have heard of Arattai. But the next app that is going viral now from Zoho is its Mail app. Many high-profile users are switching to it. Should you too and how it is different from Gmail? We explain ...

Xbox Game Pass may be a cracking deal if you're making the most of its offerings, but if you're itching to explore new horizons, it's thankfully a doddle to do so. Xbox Game Pass has always been chock ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...